Recent submissions

  • Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition 

    Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; Miranda, S; Perez-Lopez, R; Dolling, D; Robinson, D; Sandhu, S; Fowler, G; Ebbs, B; Flohr, P; Seed, G; Nava Rodrigues, D; Boysen, G; Bertan, C; Atkin, M; Crespo, M; Figueiredo, I; Riisnaes, R; Sumanasuriya, S; Rescigno, P; Zafeiriou, Z; Tunariu, N; Bianchini, D; Gillman, A; Lord, C; Hall, E; Chinnaiyan, A; Carreira, S; De Bono, J
  • Pediatric high-grade glioma: biologically and clinically in need of new thinking. 

    Jones, C; Karajannis, MA; Jones, DT; Kieran, MW; Monje, M; Baker, SJ; Becher, OJ; Cho, YJ; Gupta, N; Hawkins, C; Hargrave, D; Haas-Kogan, DA; Jabado, N; Li, XN; Mueller, S; Nicolaides, T; Packer, RJ; Persson, AI; Phillips, JJ; Simonds, EF; Stafford, JM; Tang, Y; Pfister, SM; Weiss, WA (2017-02-01)
    High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, ...
  • Undefined familial colorectal cancer and the role of pleiotropism in cancer susceptibility genes. 

    Dobbins, SE; Broderick, P; Chubb, D; Kinnersley, B; Sherborne, AL; Houlston, RS (2016-10)
    Although family history is a major risk factor for colorectal cancer (CRC) a genetic diagnosis cannot be obtained in over 50 % of familial cases when screened for known CRC cancer susceptibility genes. The genetics of ...
  • Functional variants in DCAF4 associated with lung cancer risk in European populations. 

    Liu, H; Liu, Z; Wang, Y; Stinchcombe, TE; Owzar, K; Han, Y; Hung, RJ; Brhane, Y; McLaughlin, J; Brennan, P; Bickeböller, H; Rosenberger, A; Houlston, RS; Caporaso, N; Landi, MT; Brüske, I; Risch, A; Wu, X; Ye, Y; Christiani, DC; Transdisciplinary Research in Cancer of the Lung (TRICL) Research Team; Amos, CI; Wei, Q (2017-04-05)
    Cullin-RING ubiquitin ligases (CRLs) responsible for substrate specificity of ubiquitination and play a key role in cell-cycle control and DNA damage response. In this study, we assessed associations between 16,599 SNPs ...
  • Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. 

    Pawlyn, C; Bright, MD; Buros, AF; Stein, CK; Walters, Z; Aronson, LI; Mirabella, F; Jones, JR; Kaiser, MF; Walker, BA; Jackson, GH; Clarke, PA; Bergsagel, PL; Workman, P; Chesi, M; Morgan, GJ; Davies, FE (2017-03-31)
    Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly ...
  • Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs. 

    Zhou, F; Wang, Y; Liu, H; Ready, N; Han, Y; Hung, RJ; Brhane, Y; McLaughlin, J; Brennan, P; Bickeböller, H; Rosenberger, A; Houlston, RS; Caporaso, N; Landi, MT; Brüske, I; Risch, A; Ye, Y; Wu, X; Christiani, DC; Goodman, G; Chen, C; Transdisciplinary Research in Cancer of the Lung (TRICL) Research Team; Amos, CI; Wei, Q (2017-04)
    PURPOSE: mRNA degradation is an important regulatory step for controlling gene expression and cell functions. Genetic abnormalities involved in mRNA degradation genes were found to be associated with cancer risks. Therefore, ...
  • Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. 

    Rodriguez-Broadbent, H; Law, PJ; Sud, A; Palin, K; Tuupanen, S; Gylfe, A; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, AP; Ripatti, S; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, JP; Al-Tassan, NA; Palles, C; Martin, L; Barclay, E; Farrington, SM; Timofeeva, MN; Meyer, BF; Wakil, SM; Campbell, H; Smith, CG; Idziaszczyk, S; Maughan, TS; Kaplan, R; Kerr, R; Kerr, D; Passarelli, MN; Figueiredo, JC; Buchanan, DD; Win, AK; Hopper, JL; Jenkins, MA; Lindor, NM; Newcomb, PA; Gallinger, S; Conti, D; Schumacher, F; Casey, G; Aaltonen, LA; Cheadle, JP; Tomlinson, IP; Dunlop, MG; Houlston, RS (2017-03-24)
    While elevated blood cholesterol has been associated with an increased risk of colorectal cancer (CRC) in observational studies, causality is uncertain. Here we apply a Mendelian randomisation (MR) analysis to examine the ...
  • Identification of miRSNPs associated with the risk of multiple myeloma. 

    Macauda, A; Calvetti, D; Maccari, G; Hemminki, K; Försti, A; Goldschmidt, H; Weinhold, N; Houlston, R; Andersen, V; Vogel, U; Buda, G; Varkonyi, J; Sureda, A; Lopez, JM; Watek, M; Butrym, A; Sarasquete, ME; Dudziński, M; Jurczyszyn, A; Druzd-Sitek, A; Kruszewski, M; Subocz, E; Petrini, M; Iskierka-Jażdżewska, E; Raźny, M; Szombath, G; Marques, H; Zawirska, D; Chraniuk, D; Halka, J; Hove Jacobsen, SE; Mazur, G; Sanz, RG; Dumontet, C; Moreno, V; Stępień, A; Beider, K; Pelosini, M; Reis, RM; Krawczyk-Kulis, M; Rymko, M; Avet-Loiseau, H; Lesueur, F; Grząśko, N; Ostrovsky, O; Jamroziak, K; Vangsted, AJ; Jerez, A; Tomczak, W; Zaucha, JM; Kadar, K; Pérez, JS; Nagler, A; Landi, S; Gemignani, F; Canzian, F (2016-10-08)
    Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. Multiple ...
  • Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. 

    Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; Ritchie, AW; Attard, G; Cross, W; Jones, RJ; Parker, CC; Russell, JM; Thalmann, GN; Schiavone, F; Cassoly, E; Matheson, D; Millman, R; Rentsch, CA; Barber, J; Gilson, C; Ibrahim, A; Logue, J; Lydon, A; Nikapota, AD; O'Sullivan, JM; Porfiri, E; Protheroe, A; Srihari, NN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C; Parmar, MK; Sydes, MR; STAMPEDE Investigators (2017-03-13)
    Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ...
  • PARP inhibitors: Synthetic lethality in the clinic. 

    Lord, CJ; Ashworth, A (2017-03-17)
    PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors ...
  • MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. 

    Trevisani, F; Ghidini, M; Larcher, A; Lampis, A; Lote, H; Manunta, P; Alibrandi, MT; Zagato, L; Citterio, L; Dell'Antonio, G; Carenzi, C; Capasso, G; Rugge, M; Rigotti, P; Bertini, R; Cascione, L; Briganti, A; Salonia, A; Benigni, F; Braconi, C; Fassan, M; Hahne, JC; Montorsi, F; Valeri, N (2016-11-22)
    BACKGROUND: A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic kidney disease ...
  • PARP inhibitor combination therapy. 

    Dréan, A; Lord, CJ; Ashworth, A (2016-12)
    In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with ...
  • Genomic Classification and Prognosis in Acute Myeloid Leukemia. 

    Papaemmanuil, E; Gerstung, M; Bullinger, L; Gaidzik, VI; Paschka, P; Roberts, ND; Potter, NE; Heuser, M; Thol, F; Bolli, N; Gundem, G; Van Loo, P; Martincorena, I; Ganly, P; Mudie, L; McLaren, S; O'Meara, S; Raine, K; Jones, DR; Teague, JW; Butler, AP; Greaves, MF; Ganser, A; Döhner, K; Schlenk, RF; Döhner, H; Campbell, PJ (2016-06)
    Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical ...
  • The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. 

    Liu, NQ; Ter Huurne, M; Nguyen, LN; Peng, T; Wang, SY; Studd, JB; Joshi, O; Ongen, H; Bramsen, JB; Yan, J; Andersen, CL; Taipale, J; Dermitzakis, ET; Houlston, RS; Hubner, NC; Stunnenberg, HG (2017-02-14)
    Genome-wide association studies have identified a great number of non-coding risk variants for colorectal cancer (CRC). To date, the majority of these variants have not been functionally studied. Identification of ...
  • Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10p21.2. 

    Studd, JB; Vijayakrishnan, J; Yang, M; Migliorini, G; Paulsson, K; Houlston, RS (2017-03-03)
    Despite high-hyperdiploid acute lymphoblastic leukaemia (HD-ALL) being the most common subgroup of paediatric ALL, its aetiology remains unknown. Genome-wide association studies have demonstrated association at 10q21.2. ...
  • Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures 

    Morrison, E; Wai, P; Leonidou, A; Bland, P; Khalique, S; Farnie, G; Daley, F; Peck, B; Natrajan, R (2016)
  • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016) 

    Herrera-Abreu, MT; Palafox, M; Asghar, U; Rivas, MA; Cutts, RJ; Garcia-Murillas, I; Pearson, A; Guzman, M; Rodriguez, O; Grueso, J; Bellet, M; Cortes, J; Elliott, R; Pancholi, S; Lord, CJ; Baselga, J; Dowsett, M; Martin, L-A; Turner, NC; Serra, V (2016-10)
  • DOI: 10.1093/annonc/mdx074 · License: CC BY-NC 4.0 

    Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; McDonald, A; Maka, N; Balsitis, M; Bose, N; Simbolo, M; Mafficin, A; Lampis, A; Hahne, JC; Trevisani, F; Eltahir, Z; Mentrasti, G; Findlay, C; Kalkman, EAJ; Punta, M; Werner, B; Lise, S; Aktipis, A; Maley, C; Greaves, M; Braconi, C; White, J; Fassan, M; Scarpa, A; Sottoriva, A; Valeri, N

View more